A NOVEL THERAPEUTIC TARGET FOR NEUROBLASTOMA CHILDHOOD CANCER

The development of therapies specifically dedicated to pediatric cancers is of strong priority given the limited current treatments available for the patients. As they arise in yet immature organisms, childhood cancers profoundly differ from adult cancers and suffer from insufficient preclinical models recapitulating more closely their specificities. Among the pediatric cancers, Neuroblastoma is a malignant solid tumor of the sympathetic nervous system, and is the most common type of cancer to be diagnosed in the first year of life. The most aggressive forms are devastating and remain of poor prognostic.

DESCRIPTION
The laboratory took advantage of an original model to identify a novel therapeutic target for Neuroblastoma. Expression data indicates that this target gene, which belongs to the Semaphorin protein family, is highly expressed in human metastatic neuroblastoma cell lines and patient samples. The lab conducted various assays which established that interfering with the gene, using small interfering RNAs or function-blocking antibody, strongly impact on Neuroblastoma tumor formation and cell migration.

STAGE OF DEVELOPMENT
In vitro studies

ADVANTAGES / NOVELTY
Novel therapeutic strategy for Neuroblastoma treatment
High medical need

APPLICATIONS
Neuroblastoma, Cancers derived from embryonic neural crest

INTELLECTUAL PROPERTY
Patent pending
Priority date: May 19, 2015 (FR1554440)

COLLABORATION TYPE
Pulsalys is looking for industrial partners, for further lead optimisation and offers to grant patent licences

RESEARCH TEAM
Valérie CASTELLANI
Centre de Génétique et de Physiologie Moléculaire et Cellulaire (CGphiMC) UMR CNRS 5534 UCBL